NCT01240668

Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia

Official Title:

An Observational Prospective Registry to Identify Demographic and Clinical Characteristics of Patients Hospitalized With Euvolemic and Hypervolemic Hyponatremia and Assess the Comparative Effectiveness of Available Treatments and the Impact on Resource Utilization

Summary

The registry is a multi-center, prospective, observational study designed to collect data in patients with euvolemic and hypervolemic hyponatremia in the hospital setting in the USA and hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH) in Europe; patients with hypovolemic hyponatremia will be excluded from the registry. The registry is observational in design, and the registry will collect data on patients with a serum sodium ≤130 mmol/L. Data from the patients' chart will be collected throughout the duration of the hospital, from admission to discharge, and the data will be entered into the case report form (CRF) or into an electronic data capture (EDC) system. These patients will be entered into the registry over the duration of 18 months at community, tertiary, and academic medical centers from diverse multiple regions of the USA and Europe.

A patient's treatment will be determined by their caregiver and not by this protocol. Thus, the registry will provide a unique opportunity to evaluate how the patients are managed under real-world management conditions.

Eligibility

Inclusion Criteria:

* Adults ≥18 years old who are hospitalized
* Euvolemic or hypervolemic hyponatremia with serum sodium ≤130mmol/L
* For euvolemic hyponatremia:

* Euvolemia is defined as: absence of clinical and historical evidence of extracellular fluid volume depletion or sequestration; and absence of edema and ascites; or
* Physician diagnosis of SIADH
* For hypervolemic hyponatremia (applies to USA sites only):

* Hypervolemia is defined as: excess extracellular fluid volume manifesting as dependent edema or ascites
* Patients may have one or more of the following underlying co-morbid conditions:

* Congestive heart failure
* Cirrhosis and/or liver failure
* Nephrotic syndrome

Exclusion Criteria:

* Patients with hypovolemic hyponatremia
* Use of investigational drug, biologic, or device during the study

Disease(s) and\or Condition(s)

Euvolemic Hyponatremia

Hypervolemic Hyponatremia

Primary Purpose
Intervention/Treatment
Sponsor
  • Otsuka America Pharmaceutical